AACR: Data and de-risking

IQVIA CMO Kyle Bryan’s take on what the conference signals about where technology innovation is headed in oncology

Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting in San Diego as biotechs unveiled their latest preclinical and first-in-human oncology data. On a special edition of the BioCentury This Week podcast, IQVIA Biotech CMO James Kyle Bryan joins BioCentury’s analysts to discuss what AACR revealed about modalities gaining traction, plus share his perspective on de-risking clinical development and eliminating the “white space” that delays biotechs’ timelines in the clinic.

This edition of the BioCentury This Week podcast is brought to you by IQVIA Biotech.